inspection – Page 68

Analyst training deficiency during sponsor oversight – preventing repeat GLP findings

“`html Addressing Analyst Training Deficiencies Under Sponsor Oversight to Prevent GLP Findings In the field of pharmaceutical development and manufacturing, ensuring compliance with Good Laboratory Practices (GLP) and Good Clinical…

Serialization data mismatch during distribution – recall readiness impact

Tackling Serialization Data Mismatches During Distribution: Ensuring Recall Readiness The challenge of serialization data mismatches during distribution presents a significant obstacle for pharmaceutical manufacturers. Such discrepancies can not only jeopardize…

Validation gaps identified during change control – inspection evidence expectations

Identifying and Addressing Validation Gaps During Change Control for Inspection Readiness Validation gaps occurring during change control represent a critical challenge for pharmaceutical manufacturers. When inadequacies arise in the validation…

Serialization data mismatch during distribution – preventing repeat serialization deviations

Managing Serialization Data Mismatches During Distribution to Prevent Future Deviations Serialization data mismatches can lead to serious consequences in pharmaceutical distribution, including regulatory violations and compromised product integrity. This playbook…

Change impact not assessed during lifecycle management – regulatory deficiency risk

“`html Assessing Change Impact During Lifecycle Management to Mitigate Regulatory Risks In the highly regulated pharmaceutical industry, change management is pivotal to maintaining compliance with Good Manufacturing Practices (GMP). Neglecting…

Unreported serial number events during regulatory inspection – regulatory compliance risk

Addressing Unreported Serial Number Events During Regulatory Inspections In the highly regulated landscape of pharmaceutical manufacturing, unreported serial number events can pose significant compliance risks and operational challenges. Such events,…

Validation gaps identified during system upgrades – inspection evidence expectations

Playbook for Identifying and Addressing Validation Gaps During System Upgrades Validation gaps during system upgrades can pose significant risks to compliance within pharmaceutical manufacturing. These gaps not only jeopardize production…

Raw data traceability failure during routine studies – alignment with OECD principles

Addressing Raw Data Traceability Failures During Routine Studies with OECD Principles The integrity of raw data is paramount during routine studies in pharmaceutical manufacturing and quality control. A failure in…

Unreported serial number events during system integration – preventing repeat serialization deviations

Addressing Unreported Serial Number Events During System Integration to Prevent Serialization Deviations The pharmaceutical industry often faces challenges during system integration, particularly with unreported serial number events. Such lapses can…

Change impact not assessed during change control – inspection evidence expectations

Assessing Change Impact in Change Control: A Comprehensive Playbook for Compliance In pharmaceutical manufacturing, the rigorous process of change control is fundamental to maintaining compliance and ensuring product quality. However,…

Traceability breaks in supply chain during regulatory inspection – preventing repeat serialization deviations

Mitigating Supply Chain Traceability Disruptions During Regulatory Inspections In the highly regulated pharmaceutical industry, maintaining robust traceability in the supply chain is paramount. However, traceability breaks can occur during the…

Validation gaps identified during site expansion – regulatory deficiency risk

Addressing Validation Gaps Found During Facility Expansion to Mitigate Regulatory Deficiencies With the rapid growth of the pharmaceutical industry, site expansions often create numerous challenges, particularly concerning validation protocols. Regulatory…